US20030231981A1 - Separation - Google Patents
Separation Download PDFInfo
- Publication number
- US20030231981A1 US20030231981A1 US10/409,732 US40973203A US2003231981A1 US 20030231981 A1 US20030231981 A1 US 20030231981A1 US 40973203 A US40973203 A US 40973203A US 2003231981 A1 US2003231981 A1 US 2003231981A1
- Authority
- US
- United States
- Prior art keywords
- matrix
- polymer
- acid
- porous
- porous structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
- B01J20/28054—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties characterised by their surface properties or porosity
- B01J20/28078—Pore diameter
- B01J20/28085—Pore diameter being more than 50 nm, i.e. macropores
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/14—Other self-supporting filtering material ; Other filtering material
- B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D39/00—Filtering material for liquid or gaseous fluids
- B01D39/14—Other self-supporting filtering material ; Other filtering material
- B01D39/20—Other self-supporting filtering material ; Other filtering material of inorganic material, e.g. asbestos paper, metallic filtering material of non-woven wires
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3204—Inorganic carriers, supports or substrates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/321—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
- B01J20/3206—Organic carriers, supports or substrates
- B01J20/3208—Polymeric carriers, supports or substrates
- B01J20/3212—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
- B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
- B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
- B01J20/3251—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulphur
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3244—Non-macromolecular compounds
- B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
- B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
- B01J20/3255—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising a cyclic structure containing at least one of the heteroatoms nitrogen, oxygen or sulfur, e.g. heterocyclic or heteroaromatic structures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
- B01J20/30—Processes for preparing, regenerating, or reactivating
- B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
- B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
- B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
- B01J20/3268—Macromolecular compounds
- B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
- B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
-
- C—CHEMISTRY; METALLURGY
- C02—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F—TREATMENT OF WATER, WASTE WATER, SEWAGE, OR SLUDGE
- C02F1/00—Treatment of water, waste water, or sewage
- C02F1/38—Treatment of water, waste water, or sewage by centrifugal separation
Definitions
- the present invention relates to improvements in removal of components from whole blood or a body fluid. More specifically, the invention relates to a method, wherein blood or body fluid is allowed to pass through a rigid integral separation matrix without being excluded therefrom.
- Inflammatoric processes such as sepsis, are a major cause of morbidity and mortality in humans. It is estimated that, yearly, 400 000 to 500 000 episodes of sepsis results in 100 000 to 175 000 human deaths in the U.S. alone. In Germany, sepsis rates of up to 19% of patients stationed at Intensive Care Units have been noted. Sepsis has also become the leading cause of death in intensive care units among patients with non-traumatic illnesses. Despite the major advances of the past decades in the treatment of serious infections, the incidence and mortality due to sepsis continues to rise.
- LPS lipopolysaccharide cell wall structure
- TNF- ⁇ Tumor Necrosis Factor
- Il-1 Interleukine 1
- Il-17 Interleukine 17
- endotoxins are kept within the lumen of the intestine.
- the presence of splanchic ischemia or dysoxia causes disruption of the mucosal barrier and translocation (i.e. the transport of endotoxins from the intestine to the circulation system) of endotoxins from the gut lumen to the portal circulation.
- Antibiotics of varying types are widely used to prevent and treat infections.
- an antibiotic resistance is developed among various species of bacteria. This is particularly true for the microbial flora resident in hospitals, where organisms are under a constant selective pressure to develop resistance.
- the antibiotics used are the most economical, the safest and the most easy to administer and may not have a broad enough spectrum to suppress certain infections.
- Antibiotics can be toxic to varying degrees by causing allergy, interactions with other drugs, and causing direct damage to major organs (e.g. liver, kidney). Many antibiotics also change the normal intestinal flora, which can cause diarrhea and nutritional malabsorption.
- Certain antibiotics are known to neutralize the action of endotoxins, such as polymyxin B. This antibiotic binds to the lipid A part of endotoxin and neutralizes its activity. Polymyxin is not used routinely due to its toxicity. It is only given to patients under constant supervision and monitoring of the renal function.
- an adsorbent for anti-lipid antibodies which comprises a compound with an anionic functional group immobilized onto a water-insoluble porous material.
- the porous material can be agarose, cellulose, dextran, polyacrylamide, glass, silica gel, or a hard polymer made of a styrene-divinylbenzene copolymer, and the porous material is packed as a bed of separate particles in a separation device.
- adsorbent materials In attempts to remove components from blood, different adsorbent materials have been prepared.
- An endotoxin removal adsorbent comprising a ligand immobilized on a solid phase support medium is shown in WO 01/23413.
- a preferred support medium is in the form of beads. When packed in a separation device, the solid phase support medium is porous enough to allow passage of blood cells between the beads.
- the adsorbent material has a size and a structure adapted to remove ⁇ -2 microglobulin from blood.
- the adsorbent material of this document can be a macroporous synthetic polymer with a surface of beads and of pores modified as to prevent adsorption of proteins and plateletes.
- individual spherical beads of the polymer were mechanically destroyed at a loading of about 500 g, which is obtained in for example a column packed with the beads. Such a loading results in a considerable pressure drop over of the column.
- an absorbent has been prepared in EP 464872, which comprises waterinsoluble porous hard gel particles having an exclusion limit of 10 6 -10 9 Dalton.
- the gel bed is used for selective removal of lipoproteins from blood or plasma in extracorporeal circulation treatment.
- the porous support material for endotoxin removal is beads, which can be filled into a container, the beads having a size sufficient to provide the requisite space between the beads when packed into a column or filter bed.
- the porous support material can also be microfiltration hollow-fibers or flat sheet membranes in order to minimize pressure drops.
- an adsorbent for eliminating biomacromolecules which consists of a carrier of porous spherical particles having a particle size of 50-150 microns and an exclusion limit of at least 105 Dalton.
- Polymyxin B is coupled to the particles, which are subsequently filled in a cartridge to be used in a system for extracorporeal endotoxin removal from whole blood.
- an elimination of blood cells facilitates the removal of compounds present in plasma as described above, e.g. in WO 00/62836 or WO 01/23413.
- a technique involves two separation steps which both could contribute to an enhanced risk of adverse cellular activation due to bioincompatability.
- the purpose of the present invention is to provide a new method for selective binding and separating at least one component from whole blood or body fluids, whereby the above mentioned problems in connection with inflammatoric processes are eliminated.
- Another purpose is to provide such a method, whereby the selective binding and separation can be accomplished on whole blood without the need of separating blood into plasma and blood cells.
- a further purpose of the invention is to provide such a method, which is not size-dependent, i.e. the blood components are not separated by means of exclusion.
- Still another object of the invention is to provide such a method, whereby high flow rates can be obtained in a separation device without significant pressure drop with time.
- Yet a further purpose is to provide such a method without subjecting the blood to shear forces in a separation device even at very high flow rates while maintaining a low line pressure in order to avoid damage to bloodvessels.
- a method for selectively binding and separating at least one component from whole blood or a body fluid.
- the blood or body fluid is allowed to pass through a rigid integral separation matrix without being excluded therefrom, the matrix having a porous structure with a pore size ranging from 5 micron to 500 micron and an active surface ranging from 0.5 cm 2 to 10 m 2 , which is able to bind one or several components.
- the matrix further comprises at least one functional group which has been introduced by means of coating and/or surface modification of the porous structure.
- the active surface obtained, alone or in combination with non-functionalized regions of the same is able to selectively bind at least one component of whole blood or a body fluid.
- the components to be removed can be natural as well as non-natural, i.e. a specific ligand, such as an antibody, is attached to the component.
- the functional groups obtained by means of direct or indirect selective conversion of the surface of the porous structure, have been further used for immobilization of ligands.
- the functional groups of the porous structure can be utilized as they are in the inventive method.
- the pore size as well as the surface of the skeletal-like porous structure has been adapted to be used in the separation matrix of the inventive method in connection with whole blood purification.
- the method according to the invention can also be used for the removal of components from other body fluids as well as aqueous solutions. It is an important aspect of the invention that neither any component nor any solvent is excluded from the matrix during a separation procedure.
- the rigid integral matrix should have an available surface from 0.5 cm 2 to 10 m 2 , and the density of the matrix structure is not limiting for performing the inventive method.
- the term “rigid” means that the matrix is not flexible, not bending or yielding, but able to withstand a pressure of at least 0.5 bar.
- integral means that the matrix with high surface area is an entire entity.
- the porous structure of the matrix in the inventive method is made of metal, inorganic oxide, carbon, glass, ceramic, synthetic polymer, and/or natural polymer, or mixtures thereof. Porous solid metal structures with well-defined pore sizes and high surface areas can be manufactured by using strictly controlled sintering processes that produces uniformly-sized pores.
- polyurethanes prepared from isocyanates and various other organic compounds have active hydrogen atoms, which have been used for producing poly-addition products.
- This active hydrogen can come from bifunctional or polyfunctional compounds, such as polyalcohols, polyamines. Reactions with water gives rise to primary amines which have been used for covalent immobilization of specific ligands.
- a wide variety of metals and alloys have been used, such as stainless steel, nickel, titanium, monel, inconel, hastelloy and other special metal materials.
- High surface area inorganic oxides, especially alumina and zirconia, have also been utilized with the same techniques to produce ceramic materials with defined pore structures.
- such ceramics as well as sintered glass can be purchased, which have adequate pore sizes.
- amorphous silica e.g. zeolites, and lava rock
- Natural materials and hybrides thereof which can be used as a matrix material in the inventive method, are polysaccharides, such as cellulose, and other polymeric carbohydrate materials.
- Other suitable natural polymeric materials are polyamino acids, also those involving synthetic amino acids, polylactic acid, polyglycolic acid and its copolymers with lactic acid.
- hybrid encompasses derivatives of such natural materials, for example cellulose diacetate, which is a preferred polysaccharide derivative.
- Suitable synthetic polymers for the matrix to be used in the present invention are polyolefines, such as polyethylene, polypropylene, polybutylene, polymetylpentene, and ethylene vinyl acetate copolymers; vinylic polymers, such as polyvinyl alcohol, polyvinyl acetals, and polyvinylpyrrolidone; fluorine containing polymers, such as polytetrafluoroethylene, fluorinated ethylene-propylene copolymer, polychloroflouroethylene, polyvinylfluoride, and polyvinylidene fluoride; polyacrylates, such as polymethylmethacrylate, cyanoacrylate, polyacrylonitrile, and polymetacrylates; polyamides, such as polyacrylamide; polyimides, such as polyethylenimines; polystyrene and its copolymers, such as polystyrene and acrylonitrile-butadiene-styrene-polymers; silicone
- At least one functional group has been introduced onto a porous structure of the rigid integral separation matrix.
- the functional groups can be of different kinds, i.e. of the anionic, cationic or nonionic type.
- the functional groups of the porous structure have been used to covalent bind substances like peptides/proteins and bile acids (e.g. deoxycholic acid), antibodies and fragments thereof as well as other biomolecules and substances having the ability to selectively bind endotoxins and/or proinflammatory mediators.
- a surface modification i.e. a surface functionalization in an indirect way, was accomplished by means of electro-deposition, electro-evaporation, plasma chemical deposition, deposition from an ion plasma flow, or chemical vapor deposition (e.g. plasma polymerization, plasma enhanced surface polymer deposition).
- the surface modification methods are known per se and found in “Plasma surface modification and plasma polymerization” by N. Inagaki, 1996, Technomic Publishing, Lancaster, USA. Different three-dimensional matrix structures have been treated by means of these methods, a very homogeneous modification of the active surface being achieved.
- a plasmachemical processing have also been combined with classic chemical synthesis, the selectivity of surface modifications for polymers being significantly enhanced.
- One approach has been to apply a specific plasma gas surface functionalization immediately followed by a chemical unification of the coexisting plasma functional groups.
- Another way of introducing the functional groups is by means of a direct functionalization, i.e. coating the surface with a polymeric material.
- the synthetic or natural polymer has been coated onto the high surface metal, inorganic oxide, carbon, glass, ceramic, as well as another suitable synthetic polymer, and/or a natural polymer, or mixtures thereof.
- the coating has also been accomplished by means of adhesion or adsorption of a polymeric substance having functional groups.
- a polymeric substance having functional groups examples include polylysine, polyarginine, and polyethyleneimine.
- polyethyleneimine-like substances was obtained on the porous surface.
- a separation matrix is used in the method according to the invention for selectively binding and separating at least one component from whole blood or a body fluid
- the hydrophilic as well as the hydrophobic regions of proteineous blood components can interact with the processed surface in order to remove the desired components.
- the matrix surface for selective binding and separation comprises a polyolefine, e.g. a polyethylene or polypropylene
- the positive charges of the amino groups are likewise used for electrostatic interactions and the hydrophobic regions are used for hydrophobic interactions.
- This approach is used in the inventive method for the selective binding of different regions of for example lipopolysaccharides.
- Polymers and metals having for example reactive hydroxyls, can also be functionilized by means of silanization.
- the porous structure can have hydrophilic as well as hydrophobic regions, which can interact the different blood components.
- the characteristic properties of a substance of interest are utilized when preparing the surface to be used in the method according to the invention.
- the functional groups of the active surface are sulfhydryls, carboxylates, amines, aldehydes, ketones, hydroxyls, halogens, hydrazides, and active hydrogen.
- a ligand has been coupled to the at least one functional group of the high surface porous structure in a covalent way.
- a ligand is a substance with high affinity for the component to be removed from whole blood or a body fluid.
- the ligand is used to enhance the adsorption properties and the efficacy of binding.
- the ligand can be a protein, preferably a recombinant protein, a peptide, an antibody or a fragment thereof, a carbohydrate, e.g. a polysaccharide, a hormone, an antioxidant, a glycoprotein, a lipoprotein, a lipid, a fat soluble vitamin, e.g. vitamin E, a bile acid, a reactive dye, allantoin, uric acid, or polymyxin, or combinations thereof.
- a protein preferably a recombinant protein, a peptide, an antibody or a fragment thereof, a carbohydrate, e.g. a polysaccharide, a hormone, an antioxidant, a glycoprotein, a lipoprotein, a lipid, a fat soluble vitamin, e.g. vitamin E, a bile acid, a reactive dye, allantoin, uric acid, or polymyxin, or combinations thereof.
- a suitable bile acid is deoxycholic acid, which is an endogenous hydrophobic substance.
- deoxycholic acid which is an endogenous hydrophobic substance.
- Such a bile acid can be coupled either directly to the functional groups, via a spacer, or coupled via a large molecule, and is then used for removing endotoxins from blood, body fluids and aqueous solutions as in the method according to the invention.
- a spacer is a molecule, large or small, which connects the ligand to the surface of the porous structure.
- the porous structure of the separation matrix comprises a polyolefine having an added amine-group
- this group can have an albumin coupled thereto and in turn at least one a bile acid moiety coupled to this large molecule.
- the invention also refers to a new use of a bile acid moiety immobilized on a support for eliminating a component from an aqueous solution comprising the same.
- the bile acid moiety is a deoxycholic acid moiety.
- a suitable solid support for immobilization of the bile acid moiety is a rigid integral separation matrix having a porous structure with a pore size ranging from 5 micron to 500 micron, preferably from 70 micron to 170 micron, and an active surface ranging from 0.5 cm 2 to 10 m 2 .
- the ligand of the matrix in the inventive method is albumin or an albumin produced by means of recombinant technology, which can be used instead of serum albumin, polymyxin B (i.e. charged groups on a hydrophobic structure), or deoxycholic acid.
- a ligand can also act as a spacer in the method according to the invention.
- a human recombinant protein or another large molecule e.g. hyaluronic acid
- a crosslinker is coupled between the at least one functional group and the ligand in a covalent way.
- a cross-linker is an element that covalently bonds the ligand to the supportive porous structure, the element being a spacer when linking the ligand at a distance from the porous structure itself.
- Such molecular spacers are known within the art. They have been introduced in order to increase the affinity for the component to be bound and separated from whole blood or body fluids by providing a better availability to the ligands. The biocompatibility of the surface of the porous matrix structure is also increased by the introduction of these molecular spacers.
- a crosslinker/spacer can comprise a zero-length cross-linker alone or in a combination with an intervening crosslinker, the final complex obtained being bound together by virtue of chemical substances that add structures to the crosslinked substance.
- intervening crosslinkers can be of type homobifunctional (e.g. dialdehydes), heterobifuntional (e.g. amino acids) or trifunctional crosslinking type.
- the main purpose of the spacer is to increase the bioavailability of the specific ligand used.
- the spacer can for example be a silane, a diisocyanate, a glycolate, a polyethyleneglycol, a succinimidyl reagent, a dihydrazine, adipidic acid, a diamine, an amino acid, a poly or oligo amino acid, a polyamino acid, a peptide, or a protein.
- the protein is a human recombinant protein.
- the functional groups of the cross-linker are designed to react with amino groups (Lys, Arg), with sulfhydryls (Cys), or with carboxyls (Asp, Glu), to cite a few examples.
- the active porous matrix surface is in the inventive method capable of removing for example endotoxins, alone or in combination with non-functionilized regions of the available surface of the porous structure.
- the active surface can also be used as a tool for covalent immobilization of chemicals, such as biomolecules like amino acids, polypeptides and antibodies in order to selectively enhance the elimination of such specific components.
- a separation matrix which is intended for selective removal of at least one component from whole blood or body fluids, can be produced with a porous structure of a certain pore size and/or a certain pore size range in dependence on the intended application.
- the porous structure should permit passage of blood cells.
- certain types of blood cells can also be removed from whole blood by means of the inventive method. Such cells sick cells or cells with specific surface receptors, for example activated phagocyting cells.
- the metal structure can for especial applications be magnetic.
- a magnetic matrix can for example be obtained by coating sintered magnetite with a polymer, e.g. polyethylene. An efficient removal of cells can then be performed allowing antibodies, having a magnetic dextran iron label, to attach to specific cells in the blood.
- the pore size should be within the range from 5 micron to 500 micron, preferably from 70 micron to 170 micron, most preferred from 80 micron to 100 micron, so that high flow rates can be maintained without cellular damage or cellular exclusion.
- the separation accomplished with the method according to the invention is not based on any size distribution of components. Virtually all components of whole blood or a body fluid might be eliminated by means of the inventive method.
- the secondary effectors can be cytokines (e.g. TNF- ⁇ ), interleukines (e.g. Il-1), reactive oxygen and nitrogen radicals, etc.
- cytokines e.g. TNF- ⁇
- interleukines e.g. Il-1
- reactive oxygen and nitrogen radicals etc.
- one or several separation matrixes are protected within a housing, which can have various shapes and varying and/or different in- and outlets depending on the application.
- a device can then be used for endotoxin removal and/or cytokine removal and/or cytokine neutralization. This is accomplished by passing blood or other body fluids through the device, applied intra, para, or extracorporally, without the liquid being excluded from the rigid integral separation matrix therein.
- the active surface of the porous structure, the functional groups and/or specific ligands thereon then selectively binds and separates at least one component from the liquid.
- the device can advantageously also be used for removal of endotoxins from aqueous solutions.
- An important feature of the inventive method is that all aspects of septic shock can be provided for, i.e. primary as well as secondary toxic effectors can be removed by means of the inventive method.
- a device 1 comprises a housing 2 , the housing (or cartridge) of the device being integrated into a closed circulation, in which whole blood or body fluids is circulated by means of a pump.
- the housing 2 In the housing 2 at least one separation matrix 5 a , 5 b , . . . is arranged, each intended to selectively remove one component from whole blood or body fluids.
- the housing 2 is provided with an inlet 3 and an outlet 4 , the sites of which are of no importance as long as an adequate flow is obtained within the separation matrix(es) and the housing.
- the pump is arranged upstream the inlet 3 .
- the rigid integral separation matrix can be produced in different shapes to be used in the inventive method. It can for example be designed as a disk, a rod, a cylinder, a ring, a sphere, a tube, a hollow tube, a flat sheet, or other moulded shapes.
- each separation matrix Since the flow within each separation matrix is dependent on its porosity, the contact time of the components in blood or a body fluid with the active surface can be controlled. Furthermore, a desired flow gradient can be created within a separation device by changing the porosity and configuration of the individual separation matrixes therein.
- FIG. 2 and FIG. 3 different schematic embodiments of devices are shown, which can be used when performing the method according to the invention.
- Arrows indicate the flow of blood or body fluid within the individual separation matrixes and the housings therefor, large arrows indicating a higher flow rate than small arrows.
- the separation matrixes can have the same or different porosities with or without the same or various types of functional groups or ligands in order to remove one or several components from blood or a body fluid.
- the separation matrixes are preferably integrated with the housings (each having an inlet 3 and an outlet 4 ) in order to ensure that no liquid or components therein are prevented from entering the matrix or matrixes, i.e. being excluded therefrom.
- FIGS. 2 ( a ) and ( b ) examples of one separation matrix 5 within a housing 2 are given, the matrix being of different configurations. Examples of two separation matrixes 5 a , 5 b within a housing 2 are shown in FIGS. 2 ( c ) and ( d ). In the device of FIG.
- an impermeable coating 6 such as an applied skin, on the outside periphery of the separation matrix 5 a ensures that all the material supplied to the device will pass this entire matrix.
- some of the material supplied will have a shorter residence time in the separation matrix 5 a than in the separation matrix 5 b , and vice versa.
- each device comprises several separation matrixes 5 a - 5 g .
- a partition wall 7 ensures a flow through all matrixes.
- the separation matrixes can be positioned laterally or transversally relative to their longitudinal directions, as in FIGS. 3 ( b ) and ( c ), respectively.
- the device comprises separation matrixes of different sizes.
- the inventive method can be used with an intra, para, or extracorporeally applied or stand alone device, which is thereby capable of reducing circulating endotoxins and potential harmful pro inflammatory mediators, especially TNF- ⁇ , IL-1 and IL-17, preferably in blood. It is also possible to selective remove endotoxins from other aqueous solutions.
- the components are considered to bind to the active surface of the rigid integral separation matrix by means of adhesion.
- the amount of primary amines on the porous structure surface of the obtained matrix was determined by means of trinitrobenzene sulfonic acid (TNBS) assay.
- TNBS trinitrobenzene sulfonic acid
- the aldehyde functionality of the obtained matrix was evaluated by using a catalytic acceleration of the oxidation of p-phenylenediamine by hydrogen peroxide, p-phenylenediamine being oxidized by hydrogen peroxide in an acid solution, which is known as Bandrowski's base.
- Poly-Lysine 200 mg was dissolved in 10 ml of 50 mM sodium carbonate solution and a matrix of porous polycarbonate with a porosity of 100 micron (MicroPore Plastics, USA) was then immersed into the solution and kept at 4° C. for 24 h in order to obtain a covalent bonding between the poly-lysine and the polycarbonate matrix. The porous matrix was finally washed with excess distilled water.
- the porous polyethylene matrix obtained according to Example 4 was perfused with an aqueous solution of 1-byblohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate (WCCM) (Aldrich) at a flow rate of 5 ml/min in a closed circuit at room temperature for 6 h. Then it was rinsed with water and a solution of polyethyleneimine (Sigma) (10 mg/ml, pH 7.0) was finally added and the matrix was incubated over night.
- WCCM 1-byblohexyl-3-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate
- porous polyethylene matrix obtained according to Example 3 was conjugated by using 1.0% glutardialdehyde in 0.2 M phosphate buffer, pH 7.5, and perfused at a flow rate of 1 ml/min for 6 h at room temperature. The matrix was then washed with buffer before incubation with a hyaluronic acid solution (2 mg/ml) for 16 h at room temperature. Excess hyaluronic acid was finally rinsed off.
- a matrix of porous polyethylene (Porex Technologies, Germany), having a porosity of 70 micron and an active surface of 0.18 m 2 , was perfused at a flow rate of 1 ml/min in a closed circuit for 16 h at room temperature with 2 mg/ml hyaluronic acid solution (BioHyos, Sweden, 12 ⁇ 10 6 Da) at a pH of 3.3, which was adjusted with 0.1 M HCl.
- a matrix of porous polyethylene (Porex Technologies, Germany), having a porosity of 70 micron and an active surface of 7.0 m 2 , was placed in a glass tube.
- the porous matrix was finally rinsed with reverse osmosis water.
- a matrix of porous polyethylene (Porex Technologies, Germany), having a porosity of 70 micron and an active surface of 3.4 m 2 , was placed in a glass tube.
- the tube with the the porous matrix therein was filled with a 0.2% RecombuminTM (recombinant Human Serum Albumin, HoechstPharma, USA) solution in 350 ml of reverse osmosis water and then adjusted to pH 3.3 with 0.1 M HCl.
- the RecombuminTM solution was recirculated through the tube with its filter matrix for 16 h at room temperature by using a pump at a flow rate of ⁇ 5 ml/min.
- the porous matrix was finally rinsed with reverse osmosis water.
- the surface protein content on the porous structure surface of the obtained matrix was determined by using Coomassie Brilliant Blue (BioRad, USA).
- porous polyethylene matrix obtained according to Example 4 was perfused with a polyethyleneimine (Sigma) solution, 10 mg/ml, over night at a flow rate of 5 ml/min in a closed circuit. Then, the porous matrix was rinsed with water.
- a polyethyleneimine (Sigma) solution 10 mg/ml
- the porous polyethylene matrix obtained according to Example 5 was conjugated with deoxycholate (DOC) by using an aqueous solution of WCCM.
- a solution of 6 mM WCCM in DMF:water (1:1.8) was then added over a period of 10 min. The suspension was maintained at pH 4.8 for 3 h by the addition of 0.3 M HCl.
- the DOC content on the porous structure surface of the obtained matrix was determined by using a Bile Acid Kit (Sigma).
- porous polyethylene matrix obtained according to Example 3 was conjugated by using 12% glutardialdehyde in 0.15 M phosphate buffer, pH 7.0 for 24 h at room temperature. The matrix was washed with 0.15 M phosphate buffer and then anti CD14 antibodies (DAKO, Denmark) was added at a concentration of 1 mg/ml and incubated at 8° C. for 24 h. Subsequent reduction with sodium cyanoborohydride was performed in order to produce stable secondary amine linkages.
- the antibody content on the porous structure surface of the obtained matrix was indirectly determined by means of UV spectroscopy of the antibody buffer solution before and after incubation with the porous matrix.
- porous polyethylene matrix obtained according to Example 8 was washed with 0.15 M phosphate buffer and then a recombinant IL-1 receptor (Kineret, Amgen, USA) was added at a concentration of 1 mg/ml and incubated at 8° C. for 24 h. Subsequent reduction with sodium cyanoborohydride was performed in order to produce stable secondary amine linkages.
- the IL-1 receptor content on the porous structure surface of the obtained matrix was indirectly determined by means of UV spectroscopy of the IL-1 receptor buffer solution before and after incubation with the porous matrix.
- porous polyethylene matrix obtained according to Example 5 was conjugated by using 1.0% glutardialdehyde and 0.2 M phosphate buffer, pH 7.5. The matrix was incubated with this solution for 3 h. After washing with phosphate buffer the matrix was incubated in a solution of Polymyxin B sulphate (Sigma), 1 mg/ml, over night under recirculation. The matrix was finally washed with 0.1 M phosphate buffer, pH 7.4.
- the porous polyethylene matrix obtained according to Example 2 was conjugated with recombinant TNF- ⁇ receptor (Enbrel, Wyeth, UK) at a concentration of 5 mg/ml in 0.1 M 2-(N-morpholino)ethanesulfonic acid (MES) buffer (Sigma), pH 4.8. Thirty mg/ml of an aqueous solution of WCCM was added and the matrix was incubated over night at 8° C. The matrix was finally washed with 0.1 M phosphate buffer, pH 7.4.
- MES 2-(N-morpholino)ethanesulfonic acid
- the TNF- ⁇ receptor content on the porous structure surface of the obtained matrix was indirectly determined by means of UV spectroscopy of the TNF- ⁇ receptor buffer solution before and after incubation with the porous matrix.
- the porous polyethylene matrix obtained according to Example 3 was conjugated with an anti-human TNF- ⁇ antibody (Sigma) by using a 1.0% glutardialdehyde in 0.2 M phosphate buffer, pH 7.5. The matrix was incubated with the TNF- ⁇ antibody buffer solution for 3 h. After washing of the porous matrix with phosphate buffer, the anti-human TNF- ⁇ antibody (1 mg/ml) in phosphate buffer was added and incubated at room temperature for 6 h under recirculation at a flow rate of 1 ml/min. The matrix was finally washed with 0.1 M phosphate buffer, pH 7.4.
- the TNF- ⁇ antibody content on the porous structure surface of the obtained matrix was indirectly determined by means of UV spectroscopy of the TNF- ⁇ antibody buffer solution before and after incubation with the porous matrix.
- porous polyethylene matrix obtained according to Example 5 was conjugated with human bactericidal permeability increasing protein (BPI) (Wieslab, Sweden) at a concentration of 2 mg/ml in 0.1 M MES buffer, pH 4.8.
- BPI human bactericidal permeability increasing protein
- An aqueous solution of WCCM was added to this matrix at a concentration of 15 mg/ml, and the matrix was incubated over night at 8° C.
- the matrix was finally washed with 0.1 M phosphate buffer, pH 7.4.
- the BPI content on the porous structure surface of the obtained matrix was indirectly determined by means of UV spectroscopy of the BPI buffer solution before and after incubation with the porous matrix.
- porous polyethylene matrix obtained according to Example 15 was incubated in a solution of DOC in 0.1 M MES buffer, pH 4.8, at a concentration of 1 mg/ml. Then an aqueous solution of WCCM was added, and the matrix was incubated over night at 8° C. The matrix was finally washed with 0.1 M phosphate buffer, pH 7.4.
- porous polyethylene matrix obtained according to Example 3 and was activated with 1.2% glutardialdehyde in 0.2 M phosphate buffer, pH 7.0 for 24 h at room temperature.
- the matrix was washed with buffer and subsequently incubated for 24 h in 1,6-diaminohexane (DAH) (Sigma), 50 mg/ml, in 0.2 M phosphate buffer, pH 7.0. Thereafter, 10 mg/ml sodium cyanoborohydrid (Sigma) was added to the solution.
- the porous matrix was washed with 0.1 M phosphate buffer and then incubated in a solution of DOC (1 mg/ml) in 0.1 M MES buffer, pH 4.8. Then an aqueous solution of WCCM was added and the matrix was incubated over night at 8° C. The matrix was finally washed with 0.1 M phosphate buffer, pH 7.4.
- porous polyethylene matrix obtained according to Example 5 was activated for 24 h at room temperature with 1.2% glutardialdehyde in 0.2 M phosphate buffer, pH 7.0. The matrix was washed with buffer and then incubated for 24 h with adipic dihydrazide (Aldrich) at a concentration of 10 mg/ml in 0.2 M phosphate buffer, pH 7.4. Then 10 mg/ml of sodium cyanoborohydrid (Sigma) was added to the solution.
- adipic dihydrazide Aldrich
- porous matrix was washed with 0.1 M phosphate buffer and then incubated with a solution of DOC at a concentration of 1 mg/ml in 0.1 M MES buffer, pH 4.8. Then an aqueous solution of WCCM was added, and the matrix was incubated over night at 8° C. The matrix was finally washed with 0.1 M phosphate buffer, pH 7.4.
- the matrix obtained according to Example 10 was conjugated with DOC by using an aqueous solution of WCCM.
- the pH of the suspension was adjusted to 4.8 with 0.3 M HCl.
- a 6 mM solution of WCCM in DMF:water (1:1.8) was added over a period of 10 min and the suspension was maintained at pH 4.8 for 3 h by the periodic addition of 0.3 M HCl. Then it was kept at room temperature for 24 h.
- the matrix obtained according to Example 14 was activated for 10 h at room temperature with 1.2% glutardialdehyde in 0.2 M phosphate buffer, pH 7.0, and then rinsed with excessive amounts of buffer.
- the matrix was then washed with buffer and conjugated with DOC by using an aqueous solution of WCCM.
- the pH was adjusted to 4.8 with 0.3 M HCl.
- a 6 mM solution of WCCM in DMF:water (1:1.8) was then added over a period of 10 min.
- the suspension was maintained at pH 4.8 for 3 h by the periodic addition of 0.3 M HCl. Then it was kept at room temperature for 24 h.
- the porous polyethylene matrix obtained according to Example 3 was activated for 24 h at room temperature with 1.2% glutardialdehyde in 0.2 M phosphate buffer, pH 7.0. The matrix was then washed with the buffer and incubated for 24 h with 1,6-diaminohexane (DAH) (Sigma) at a concentration of 50 mg/ml in 0.2 M phosphate buffer, pH 7.0. The porous matrix was then washed with 0.1 M phosphate buffer and incubated for 12 h at 8° C. as a suspension in a solution of TNF- ⁇ receptor (Enbrel, Wyeth, UK) at a concentration of 10 mg/ml in 0.1 M phosphate buffer, pH 7.4. Then a solution of sodium cyanoborohydrid (Sigma) at a concentration of 10 mg/ml was added to the suspension. The matrix was finally washed with 0.1 M phosphate buffer, pH 7.4.
- DASH 1,6-diaminohexane
- the TNF- ⁇ receptor content on the porous structure surface of the obtained matrix was indirectly determined by means of UV spectroscopy of the TNF- ⁇ receptor buffer solution before and after incubation with the porous matrix.
- Cell separations were performed by allowing whole blood to pass through a filter of a matrix shaped as a disk and having an active surface of 0.02 m 2 .
- a container 8 filled with up to 2 l of whole blood or plasma, was connected to a pump 9 , a pressure monitor 10 and a filter device 1 with up to 40 matrix plates, i.e. an active surface of up to 7 m 2 being provided, which has a porosity between 70 and 130 micron.
- a magnetic porous matrix comprising a mixture of polyethylene and magnetic ferrite (80% FeO, 20% BaO 2 , Porex Technologies, Germany), which had a porosity of 100 micron, was used to separate leukocytes from whole blood by using specifically labeled anti CD45+ antibodies (MACS Antibody Microbeads; Miltenyi Biotec, Germany). After a magnetic labeling of the leukocytes with such antibodies, the blood was allowed to pass through the porous matrix.
- MCS Antibody Microbeads Miltenyi Biotec, Germany
- TNF- ⁇ The elimination of TNF- ⁇ from whole blood was investigated after immobilizing polyclonal antibodies against TNF- ⁇ with glutardialdehyde onto the amino groups on the porous polymer structure. Production of TNF- ⁇ was induced by the addition of LPS to the blood and the activated whole blood was perfused over the immobilized filter in the device.
- TNF- ⁇ in whole blood was determined pre ( ⁇ ) and post ( ⁇ ) the device by an enzyme immunoassay (Enzymimmuno-assay, Milenia Biotec GmbH, Germany) in order to study the uptake of TNF- ⁇ by the filter disks. As seen, a considerable reduction of pathological concentrations of TNF- ⁇ in whole blood could be obtained.
- the matrix obtained according to Example 25 i.e. a plasma modified polyethylene matrix having DOC thereon, was immobilized thereon via a spacer of diaminohexane, which first had been coupled to the matrix by glutardialdhyde and then to the deoxycholate by using carbodiimide.
- the obtained matrix was used as porous disks in the filter device of the system shown in FIG. 4.
- the amount of LPS in plasma was determined by means of means of a Limulus Amebocyte Lysate assay (Endochrome-K, Charles River Laboratories Inc. USA) in the bulk at different time intervals during recirculation through the filter device.
- FIG. 6 the reduction of the amount of endotoxin (pg/ml) with time is shown. After a recirculation of 2 h the endotoxin load was reduced from 75 pg/ml at start to 15 pg/ml, which is the detection limit.
- Example 3 nonimmobilized amino groups
- Example 17 immobilized DOC
- Example 19 The matrixes obtained according to Example 19 and Example 29 were used for the combined removal of TNF- ⁇ and IL-1, respectively.
- Table 2 below shows a summary of the versatile applicability and the considerable efficacy of the inventive method for selective binding and separation of different components from whole blood or a body fluid.
- different porous matrixes have been used as supports for the attachment of ligands, with or without a spacer.
- methods of immobilization have been performed with glutardialdehyd by using two terminal —NH 2 and with 1-ethyl-3 (3-dimethylaminopropyl)carbodiimide with one terminal —NH 2 and one terminal —OH or —COOH, respectively.
- silane coupling reagents for specific binding of amino groups, antibodies, enzymes, peptides, proteins have also been used, aldehyde groups reacting spontaneously with amines, peptides and proteins.
- TNF- ⁇ Receptor TNF- ⁇ 61.8 Polyethylene —OH Sil.ald. Interleukine-1 IL-1 62.0 Receptor Polyethylene —OH Sil.ald. Thrombomodulin Thrombin 73.7 Polyethylene —OH Sil.ald. BPI LPS 89.3 Polyethylene HA DAH DOC LPS 29.6 Polyethylene Poly- DAH DOC LPS 73.3 Lys Polyethylene Recom- — DOC LPS 20.8 bumin Polyethylene —NH 2 GDA Anti CD 11b Ab Granulo- 50.2 cytes and monocytes Polyethylene —OH Sil.ald.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Cardiology (AREA)
- Inorganic Chemistry (AREA)
- Geology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Water Supply & Treatment (AREA)
- Hydrology & Water Resources (AREA)
- Environmental & Geological Engineering (AREA)
- Mechanical Engineering (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- External Artificial Organs (AREA)
- Separation By Low-Temperature Treatments (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/491,886 US7601134B2 (en) | 2002-04-25 | 2006-07-24 | Separation |
US12/036,603 US7910002B2 (en) | 2002-04-25 | 2008-02-25 | Separation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0201257A SE0201257D0 (sv) | 2002-04-25 | 2002-04-25 | Improved Separation |
SE0201257-3 | 2002-04-25 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/491,886 Division US7601134B2 (en) | 2002-04-25 | 2006-07-24 | Separation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20030231981A1 true US20030231981A1 (en) | 2003-12-18 |
Family
ID=20287687
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/409,732 Abandoned US20030231981A1 (en) | 2002-04-25 | 2003-04-09 | Separation |
US11/491,886 Expired - Lifetime US7601134B2 (en) | 2002-04-25 | 2006-07-24 | Separation |
US12/036,603 Expired - Lifetime US7910002B2 (en) | 2002-04-25 | 2008-02-25 | Separation |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/491,886 Expired - Lifetime US7601134B2 (en) | 2002-04-25 | 2006-07-24 | Separation |
US12/036,603 Expired - Lifetime US7910002B2 (en) | 2002-04-25 | 2008-02-25 | Separation |
Country Status (16)
Country | Link |
---|---|
US (3) | US20030231981A1 (ko) |
EP (2) | EP1704880B1 (ko) |
JP (4) | JP2006508703A (ko) |
KR (2) | KR20080044359A (ko) |
CN (2) | CN101049522B (ko) |
AT (1) | ATE329687T1 (ko) |
AU (1) | AU2003217134C1 (ko) |
BR (1) | BR0309349A (ko) |
CA (2) | CA2481711C (ko) |
DE (2) | DE60328541D1 (ko) |
ES (2) | ES2266797T3 (ko) |
HK (2) | HK1081138A1 (ko) |
MX (1) | MXPA04010543A (ko) |
RU (2) | RU2311183C2 (ko) |
SE (1) | SE0201257D0 (ko) |
WO (1) | WO2003090924A1 (ko) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006025556A1 (en) * | 2004-08-31 | 2006-03-09 | Showa Denko K.K. | Surface-modified packing material for liquid chromatography and production method thereof |
US20080020011A1 (en) * | 2004-11-19 | 2008-01-24 | Zvi Finkelstein | Therapeutic implant |
US20090093713A1 (en) * | 2007-10-04 | 2009-04-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Vasculature and lymphatic system imaging and ablation associated with a local bypass |
US20090093807A1 (en) * | 2007-10-03 | 2009-04-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Vasculature and lymphatic system imaging and ablation |
US20090093728A1 (en) * | 2007-10-05 | 2009-04-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Vasculature and lymphatic system imaging and ablation associated with a reservoir |
US20090181200A1 (en) * | 2007-09-19 | 2009-07-16 | Borenstein Jeffrey T | Microfluidic Structures for Biomedical Applications |
US20100217172A1 (en) * | 2009-02-25 | 2010-08-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US20100255057A1 (en) * | 2009-02-25 | 2010-10-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device for actively removing a target cell from blood or lymph of a vertebrate subject |
US20100252528A1 (en) * | 2006-07-03 | 2010-10-07 | Fuji Xerox Co., Ltd. | Liquid droplet ejection head, apparatus for ejecting liquid droplet, and method of producing liquid droplet ejection head |
US8317737B2 (en) | 2009-02-25 | 2012-11-27 | The Invention Science Fund I, Llc | Device for actively removing a target component from blood or lymph of a vertebrate subject |
US8721618B2 (en) | 2009-02-25 | 2014-05-13 | The Invention Science Fund I, Llc | Device for actively removing a target cell from blood or lymph of a vertebrate subject |
US20150148526A1 (en) * | 2012-05-31 | 2015-05-28 | Agency For Science, Technology And Research | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives |
US20150184132A1 (en) * | 2012-05-31 | 2015-07-02 | Agency For Science, Technology And Research | Selective binding of biological targets to solid phase ureides |
WO2015138850A1 (en) * | 2014-03-13 | 2015-09-17 | Halaka Folim G | Purification columns and methods |
CN110824157A (zh) * | 2019-11-14 | 2020-02-21 | 广州科方生物技术股份有限公司 | 一种用于免疫层析检测试剂盒的快速分离红细胞的方法 |
US10786615B2 (en) * | 2016-03-02 | 2020-09-29 | Exthera Medical Corporation | Method for treating drug intoxication |
US20210316240A1 (en) * | 2018-09-04 | 2021-10-14 | Karl Leibinger Medizintechnik Gmbh & Co. Kg | Laser-sintered filter, method for producing the filter, and method for ensuring fluid flow |
US11680080B2 (en) | 2014-03-13 | 2023-06-20 | Folim G. Halaka | Purification columns and methods |
US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2558515C (en) * | 2004-03-05 | 2013-12-03 | Sirs-Lab Gmbh | Method of enriching and/or separating prokaryotic dna by means of a protein which specifically binds dna containing non-methylated cpg motifs |
EP1792635B1 (en) * | 2004-08-30 | 2014-05-21 | Kaneka Corporation | Granulocyte adsorbent |
DE102004062535A1 (de) * | 2004-12-24 | 2006-07-06 | Forschungszentrum Karlsruhe Gmbh | Semipermeables Membransystem für magnetische Partikelfraktionen |
US7790803B2 (en) * | 2008-06-02 | 2010-09-07 | Uop Llc | Crosslinked organic-inorganic hybrid membranes and their use in gas separation |
DE102009034150A1 (de) * | 2009-07-20 | 2011-01-27 | Fresenius Medical Care Deutschland Gmbh | Adsorbens zur Adsorption von Hepcidin |
AT509192B1 (de) * | 2010-06-24 | 2011-07-15 | Zentrum Fuer Biomedizinische Technologie Der Donau Uni Krems | Sorptionsmittel für endotoxine |
EP2707055B1 (en) * | 2011-05-09 | 2019-10-23 | The University of Miami | Reducing soluble urokinase receptor in the circulation |
CN102441363A (zh) * | 2011-09-28 | 2012-05-09 | 南开大学 | 一种用于清除血液中癌细胞的吸附剂 |
GB201203546D0 (en) * | 2012-02-29 | 2012-04-11 | Whatman Gmbh | Membrane filter and a method of manufacturing the same |
EP2679302A1 (de) | 2012-06-28 | 2014-01-01 | Zentrum für biomedizinische Technologie der Donau- Universität Krems | Selektives Sorptionsmittel für die extrakorporale Blutreinigung |
KR101427700B1 (ko) * | 2012-06-29 | 2014-08-07 | 주식회사 아모그린텍 | 사이토카인 흡착시트, 그 제조방법 및 이를 이용한 혈액 필터 |
JP2014061284A (ja) * | 2012-08-31 | 2014-04-10 | Asahi Kasei Medical Co Ltd | 臓器炎症抑制用基材及びデバイス |
JP5592450B2 (ja) * | 2012-09-18 | 2014-09-17 | 大日精化工業株式会社 | 自走細胞捕捉具 |
WO2014059323A1 (en) * | 2012-10-12 | 2014-04-17 | Advantageous Systems Llc | Immobilization of particles on a matrix |
DE102012020615A1 (de) * | 2012-10-19 | 2014-04-24 | Hydac Filtertechnik Gmbh | Verfahren zur Oberflächenbehandlung eines Filtermediums |
RU2537860C2 (ru) * | 2013-01-09 | 2015-01-10 | Федеральное государственное бюджетное учреждение науки Институт металлоорганической химии им. Г.А. Разуваева Российской академии наук (ИМХ РАН) | Фотополимеризующаяся композиция для одностадийного получения полимерного нанопористого материала с гидрофобной поверхностью пор, нанопористый полимерный материал с селективными сорбирующими свойствами, способ его получения, способ одностадийного формирования на его основе водоотделяющих фильтрующих элементов и способ очистки органических жидкостей от воды |
CN103303997B (zh) * | 2013-06-14 | 2015-04-22 | 湖北大学 | 一种磁固相萃取剂在处理染料废水中的用途 |
EP3013445B1 (en) * | 2013-06-24 | 2019-11-06 | ExThera Medical Corporation | Blood filtration system containing mannose coated substrate |
US10905818B2 (en) * | 2014-03-31 | 2021-02-02 | Zoll Medical Corporation | Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome |
WO2016040850A1 (en) * | 2014-09-11 | 2016-03-17 | Oregon State University | Microfluidic device for removal of constituents from blood |
CA2962762C (en) * | 2014-09-29 | 2019-01-15 | Asahi Kasei Medical Co., Ltd. | Hollow-fiber membrane blood purification device |
AU2017311836B2 (en) * | 2016-08-18 | 2020-04-30 | Asahi Kasei Medical Co., Ltd. | Filter element for blood processing filter, blood processing filter and leukocyte removal method |
JP7309470B2 (ja) * | 2018-07-02 | 2023-07-18 | 旭化成メディカル株式会社 | 血液処理用ビーズ |
WO2020009008A1 (ja) * | 2018-07-02 | 2020-01-09 | 旭化成メディカル株式会社 | 血液処理用ビーズ |
WO2020018005A1 (en) * | 2018-07-17 | 2020-01-23 | Limited Liability Company "Gero" | Devices, methods, compositions and systems for the treatment of aging and age- related disorders |
CN116390782A (zh) | 2020-10-01 | 2023-07-04 | 阿尔特克医药股份公司 | 用于选择性结合来自体液的至少一组分的基质 |
RU2765188C1 (ru) * | 2020-11-03 | 2022-01-26 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ получения селективного сорбента для твердофазной экстракции |
EP4251230A1 (en) | 2020-11-30 | 2023-10-04 | Alteco Medical AB | Device for binding and separation of at least one component from a body fluid |
CN112755973B (zh) * | 2020-12-16 | 2023-03-10 | 重庆天外天生物技术有限公司 | 一种应用于血液净化领域的复合型吸附材料及其制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3994799A (en) * | 1973-04-17 | 1976-11-30 | Yao Shang J | Blood and tissue detoxification apparatus |
US5855782A (en) * | 1993-08-10 | 1999-01-05 | Falkenhagen; Dieter | Arrangement for removing substances from liquids, in particular blood |
US5989420A (en) * | 1994-12-27 | 1999-11-23 | Yuugengaisya Mikazuki Bunkakaikan | Porous ceramic filter, method of manufacturing the same, ceramic filter manufacturing extrusion molding die and extrusion molding apparatus using the die |
US6022477A (en) * | 1997-11-14 | 2000-02-08 | New Jersey Institute Of Technology | Method and apparatus for isolation purification of biomolecules |
US6497675B1 (en) * | 2000-04-17 | 2002-12-24 | Renal Tech International Llc | Device for extracorporeal treatment of physiological fluids of organism |
US6616623B1 (en) * | 1997-07-02 | 2003-09-09 | Idializa Ltd. | System for correction of a biological fluid |
US6796954B2 (en) * | 2000-12-04 | 2004-09-28 | Terumo Kabushiki Kaisha | Method for preparing leucocyte-free blood preparation and blood administration set |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5434341U (ko) * | 1977-08-10 | 1979-03-06 | ||
JPS5714357A (en) * | 1980-06-30 | 1982-01-25 | Asahi Chemical Ind | Catching material for lymphocyte |
US4433059A (en) * | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
CA1221307A (en) | 1982-12-02 | 1987-05-05 | Nobutaka Tani | Adsorbent and process for preparing the same |
US4656254A (en) * | 1985-12-02 | 1987-04-07 | Miles Laboratories, Inc. | Method of preparing alpha-1-proteinase inhibitor and antithrombin III |
DE3617672C2 (de) * | 1986-05-26 | 2000-02-17 | Claus Heuck | Verfahren zur Herstellung eines Reagenz, ein danach hergestelltes Reagenz sowie dessen Verwendung zur Bindung von Polymeren und Mikroorganismen aus wäßrigen Lösungen |
WO1989003885A1 (en) * | 1987-10-27 | 1989-05-05 | Centocor, Inc. | Method of removing endotoxin contaminants |
JPH0622633B2 (ja) | 1987-10-30 | 1994-03-30 | 鐘淵化学工業株式会社 | 吸着体およびそれを用いた除去装置 |
JPH0246858A (ja) * | 1988-08-08 | 1990-02-16 | Terumo Corp | 体液処理装置 |
US5153166A (en) * | 1988-08-18 | 1992-10-06 | Trustees Of At Biochem | Chromatographic stationary supports |
DE3932971C2 (de) * | 1989-10-03 | 2003-03-13 | Fresenius Ag | Zur Eliminierung von Biomakromolekülen, insbesondere LDL und Endotoxinen, aus Vollblut in extrakorporalem Kreislauf geeignetes Adsorbens |
US5476715A (en) * | 1989-10-03 | 1995-12-19 | Fresenius Ag | Particulate adsorbent for the removal of biomacromolecules such as LDL and endotoxins from whole blood in extracorporeal circuits |
EP0640351A1 (en) * | 1993-07-26 | 1995-03-01 | Duphar International Research B.V | Method for the separtion of bacterial lipopolysaccharides from protein-containing solutions |
CA2127605A1 (en) * | 1993-12-23 | 1995-06-24 | Peter J. Degen | Affinity separation method |
JP3615785B2 (ja) * | 1994-04-28 | 2005-02-02 | テルモ株式会社 | Hiv及びその関連物質除去材料 |
JPH1076004A (ja) * | 1996-09-05 | 1998-03-24 | Kanegafuchi Chem Ind Co Ltd | 体液処理用吸着材及び体液処理用吸着器 |
US6416487B1 (en) | 1997-07-30 | 2002-07-09 | Renal Tech International Llc | Method of removing beta-2 microglobulin from blood |
JP3635654B2 (ja) * | 1997-12-26 | 2005-04-06 | ニプロ株式会社 | 血液成分採取器具 |
US6576478B1 (en) * | 1998-07-14 | 2003-06-10 | Zyomyx, Inc. | Microdevices for high-throughput screening of biomolecules |
SE9901825D0 (sv) * | 1999-05-20 | 1999-05-20 | Amersham Pharm Biotech Ab | Foamed material filled with inner material |
CN2385290Y (zh) * | 1999-07-07 | 2000-06-28 | 海尔集团公司 | 板式空气换热器 |
US6774102B1 (en) * | 1999-09-29 | 2004-08-10 | Gambro Dialysatoren Gmbh & Co. Kg | Extracorporeal endotoxin removal method |
JP2003525736A (ja) * | 2000-03-07 | 2003-09-02 | エムアーテー アツォルプツィオーン テヒノロギース ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディートゲゼルシャフト | クロスフロー及びデッドエンドの構成の膜エレメントを有するモジュール |
JP2001276212A (ja) * | 2000-03-30 | 2001-10-09 | Terumo Corp | 血液成分採取方法および血液成分採取回路 |
JP2001321365A (ja) * | 2000-05-16 | 2001-11-20 | Fuji Photo Film Co Ltd | 血漿又は血清採取具 |
JP2001347116A (ja) * | 2000-06-09 | 2001-12-18 | Asahi Medical Co Ltd | 白血球除去フィルター装置 |
US6408894B1 (en) | 2001-04-25 | 2002-06-25 | Renaltech International, Llc | Method of producing devices for blood purification |
EP2035061A4 (en) * | 2006-06-16 | 2012-02-01 | Glycorex Transplantation Ab | ADSORPTION DEVICE |
-
2002
- 2002-04-25 SE SE0201257A patent/SE0201257D0/xx unknown
-
2003
- 2003-04-04 RU RU2004134345/15A patent/RU2311183C2/ru active
- 2003-04-04 ES ES03713168T patent/ES2266797T3/es not_active Expired - Lifetime
- 2003-04-04 WO PCT/SE2003/000553 patent/WO2003090924A1/en active IP Right Grant
- 2003-04-04 CN CN200710086317.1A patent/CN101049522B/zh not_active Expired - Fee Related
- 2003-04-04 CN CNB038093359A patent/CN1308068C/zh not_active Expired - Lifetime
- 2003-04-04 ES ES06008934T patent/ES2328386T3/es not_active Expired - Lifetime
- 2003-04-04 CA CA2481711A patent/CA2481711C/en not_active Expired - Lifetime
- 2003-04-04 EP EP06008934A patent/EP1704880B1/en not_active Expired - Lifetime
- 2003-04-04 DE DE60328541T patent/DE60328541D1/de not_active Expired - Lifetime
- 2003-04-04 CA CA002680643A patent/CA2680643A1/en not_active Abandoned
- 2003-04-04 AU AU2003217134A patent/AU2003217134C1/en not_active Expired
- 2003-04-04 AT AT03713168T patent/ATE329687T1/de active
- 2003-04-04 DE DE60306135T patent/DE60306135T2/de not_active Expired - Lifetime
- 2003-04-04 KR KR1020087010746A patent/KR20080044359A/ko not_active Application Discontinuation
- 2003-04-04 JP JP2003587542A patent/JP2006508703A/ja active Pending
- 2003-04-04 KR KR1020047017107A patent/KR100950432B1/ko active IP Right Grant
- 2003-04-04 MX MXPA04010543A patent/MXPA04010543A/es active IP Right Grant
- 2003-04-04 BR BR0309349-2A patent/BR0309349A/pt not_active Application Discontinuation
- 2003-04-04 EP EP03713168A patent/EP1497025B1/en not_active Expired - Lifetime
- 2003-04-09 US US10/409,732 patent/US20030231981A1/en not_active Abandoned
-
2006
- 2006-01-26 HK HK06101188A patent/HK1081138A1/xx not_active IP Right Cessation
- 2006-07-24 US US11/491,886 patent/US7601134B2/en not_active Expired - Lifetime
-
2007
- 2007-03-21 RU RU2007110420/05A patent/RU2429902C2/ru not_active IP Right Cessation
-
2008
- 2008-02-22 HK HK08101977.7A patent/HK1111369A1/zh not_active IP Right Cessation
- 2008-02-25 US US12/036,603 patent/US7910002B2/en not_active Expired - Lifetime
-
2010
- 2010-12-28 JP JP2010293995A patent/JP2011083632A/ja not_active Withdrawn
-
2014
- 2014-03-12 JP JP2014048786A patent/JP2014111203A/ja not_active Withdrawn
-
2016
- 2016-03-17 JP JP2016053835A patent/JP2016120333A/ja active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3994799A (en) * | 1973-04-17 | 1976-11-30 | Yao Shang J | Blood and tissue detoxification apparatus |
US5855782A (en) * | 1993-08-10 | 1999-01-05 | Falkenhagen; Dieter | Arrangement for removing substances from liquids, in particular blood |
US5989420A (en) * | 1994-12-27 | 1999-11-23 | Yuugengaisya Mikazuki Bunkakaikan | Porous ceramic filter, method of manufacturing the same, ceramic filter manufacturing extrusion molding die and extrusion molding apparatus using the die |
US6616623B1 (en) * | 1997-07-02 | 2003-09-09 | Idializa Ltd. | System for correction of a biological fluid |
US6022477A (en) * | 1997-11-14 | 2000-02-08 | New Jersey Institute Of Technology | Method and apparatus for isolation purification of biomolecules |
US6497675B1 (en) * | 2000-04-17 | 2002-12-24 | Renal Tech International Llc | Device for extracorporeal treatment of physiological fluids of organism |
US6796954B2 (en) * | 2000-12-04 | 2004-09-28 | Terumo Kabushiki Kaisha | Method for preparing leucocyte-free blood preparation and blood administration set |
Cited By (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006025556A1 (en) * | 2004-08-31 | 2006-03-09 | Showa Denko K.K. | Surface-modified packing material for liquid chromatography and production method thereof |
US20080020011A1 (en) * | 2004-11-19 | 2008-01-24 | Zvi Finkelstein | Therapeutic implant |
US20100252528A1 (en) * | 2006-07-03 | 2010-10-07 | Fuji Xerox Co., Ltd. | Liquid droplet ejection head, apparatus for ejecting liquid droplet, and method of producing liquid droplet ejection head |
US8176630B2 (en) * | 2006-07-03 | 2012-05-15 | Fuji Xerox Co., Ltd. | Method of producing liquid droplet ejection head |
US10265698B2 (en) | 2007-09-19 | 2019-04-23 | The Charles Stark Draper Laboratory, Inc. | Microfluidic structures for biomedical applications |
US20090181200A1 (en) * | 2007-09-19 | 2009-07-16 | Borenstein Jeffrey T | Microfluidic Structures for Biomedical Applications |
US8266791B2 (en) * | 2007-09-19 | 2012-09-18 | The Charles Stark Draper Laboratory, Inc. | Method of fabricating microfluidic structures for biomedical applications |
US9181082B2 (en) * | 2007-09-19 | 2015-11-10 | The Charles Stark Draper Laboratory, Inc. | microfluidic structures for biomedical applications |
US20130004386A1 (en) * | 2007-09-19 | 2013-01-03 | Borenstein Jeffrey T | Fabricating microfluidic structures for biomedical applications |
US20090093807A1 (en) * | 2007-10-03 | 2009-04-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Vasculature and lymphatic system imaging and ablation |
US8165663B2 (en) | 2007-10-03 | 2012-04-24 | The Invention Science Fund I, Llc | Vasculature and lymphatic system imaging and ablation |
US8285366B2 (en) | 2007-10-04 | 2012-10-09 | The Invention Science Fund I, Llc | Vasculature and lymphatic system imaging and ablation associated with a local bypass |
US20090093713A1 (en) * | 2007-10-04 | 2009-04-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Vasculature and lymphatic system imaging and ablation associated with a local bypass |
US20090093728A1 (en) * | 2007-10-05 | 2009-04-09 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Vasculature and lymphatic system imaging and ablation associated with a reservoir |
US8285367B2 (en) | 2007-10-05 | 2012-10-09 | The Invention Science Fund I, Llc | Vasculature and lymphatic system imaging and ablation associated with a reservoir |
US20100298766A1 (en) * | 2009-02-25 | 2010-11-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device for passively removing a target component from blood or lymph of a vertebrate subject |
US20100217173A1 (en) * | 2009-02-25 | 2010-08-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US8246565B2 (en) | 2009-02-25 | 2012-08-21 | The Invention Science Fund I, Llc | Device for passively removing a target component from blood or lymph of a vertebrate subject |
US8192385B2 (en) | 2009-02-25 | 2012-06-05 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US8172826B2 (en) | 2009-02-25 | 2012-05-08 | The Invention Science Fund I, Llc | Device for actively removing a target cell from blood or lymph of a vertebrate subject |
US8167871B2 (en) | 2009-02-25 | 2012-05-01 | The Invention Science Fund I, Llc | Device for actively removing a target cell from blood or lymph of a vertebrate subject |
US8308672B2 (en) | 2009-02-25 | 2012-11-13 | The Invention Science Fund I, Llc | Device for passively removing a target component from blood or lymph of a vertebrate subject |
US8317737B2 (en) | 2009-02-25 | 2012-11-27 | The Invention Science Fund I, Llc | Device for actively removing a target component from blood or lymph of a vertebrate subject |
US20100255057A1 (en) * | 2009-02-25 | 2010-10-07 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device for actively removing a target cell from blood or lymph of a vertebrate subject |
US8430831B2 (en) | 2009-02-25 | 2013-04-30 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US8454547B2 (en) | 2009-02-25 | 2013-06-04 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US8721618B2 (en) | 2009-02-25 | 2014-05-13 | The Invention Science Fund I, Llc | Device for actively removing a target cell from blood or lymph of a vertebrate subject |
US20100217172A1 (en) * | 2009-02-25 | 2010-08-26 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US8206330B2 (en) * | 2009-02-25 | 2012-06-26 | The Invention Science Fund I, Llc | Device, system, and method for controllably reducing inflammatory mediators in a subject |
US9125974B2 (en) | 2009-02-25 | 2015-09-08 | The Invention Science Fund I, Llc | Device for passively removing a target component from blood or lymph of a vertebrate subject |
US9061094B2 (en) | 2009-02-25 | 2015-06-23 | The Invention Science Fund I, Llc | Device for passively removing a target component from blood or lymph of a vertebrate subject |
US8758324B2 (en) | 2010-03-05 | 2014-06-24 | The Invention Science Fund I, Llc | Device for actively removing a target cell from blood or lymph of a vertebrate subject |
US8758330B2 (en) | 2010-03-05 | 2014-06-24 | The Invention Science Fund I, Llc | Device for actively removing a target cell from blood or lymph of a vertebrate subject |
US20150184132A1 (en) * | 2012-05-31 | 2015-07-02 | Agency For Science, Technology And Research | Selective binding of biological targets to solid phase ureides |
US20150148526A1 (en) * | 2012-05-31 | 2015-05-28 | Agency For Science, Technology And Research | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives |
US9637724B2 (en) * | 2012-05-31 | 2017-05-02 | Agency For Science, Technology And Research | Selective binding of biological targets to solid phase ureides |
US10246506B2 (en) * | 2012-05-31 | 2019-04-02 | Agency For Science, Technology And Research | Methods for reducing levels of protein-contaminant complexes and aggregates in protein preparations by treatment with electropositive organic additives |
WO2015138850A1 (en) * | 2014-03-13 | 2015-09-17 | Halaka Folim G | Purification columns and methods |
US11680080B2 (en) | 2014-03-13 | 2023-06-20 | Folim G. Halaka | Purification columns and methods |
US10786615B2 (en) * | 2016-03-02 | 2020-09-29 | Exthera Medical Corporation | Method for treating drug intoxication |
US11911551B2 (en) | 2016-03-02 | 2024-02-27 | Exthera Medical Corporation | Method for treating drug intoxication |
US20210316240A1 (en) * | 2018-09-04 | 2021-10-14 | Karl Leibinger Medizintechnik Gmbh & Co. Kg | Laser-sintered filter, method for producing the filter, and method for ensuring fluid flow |
CN110824157A (zh) * | 2019-11-14 | 2020-02-21 | 广州科方生物技术股份有限公司 | 一种用于免疫层析检测试剂盒的快速分离红细胞的方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7910002B2 (en) | Separation | |
JP7184864B2 (ja) | 高流量を用いて血液から細菌を除去するための方法 | |
AU729964B2 (en) | Affinity membrane system and method of using same | |
JP4709452B2 (ja) | エンドトキシンの体外除去方法 | |
JP2004516896A (ja) | 細胞外体液からの特異的生体高分子物質の体外捕獲 | |
WO2006106972A1 (ja) | 吸着材および体外循環用カラム | |
SE526038C2 (sv) | Polymeraffinitetsmatris, förfarande för framställning därav och anvädning därav | |
JP2005532130A (ja) | 敗血症治療のための体外流動膨張床方法 | |
AU2008201015B2 (en) | Improved separation | |
US20200378948A1 (en) | Device for the capture and removal of disease material from fluids | |
JP2814399B2 (ja) | 全血処理用吸着器 | |
RU2448897C1 (ru) | Способ комплексной очистки физиологических жидкостей | |
US6803183B2 (en) | Method for removing pyrogens from plasma and blood for treatment of septic shock | |
RU2684639C1 (ru) | Способ удаления эндотоксинов из биологических жидкостей с помощью ковалентно иммобилизованного лизоцима в качестве лиганда | |
JPS63200770A (ja) | 免疫グロブリン吸着剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALTECO MEDICAL AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JOHNSON, BO;LJUNGGREN, LENNART;REEL/FRAME:014312/0983 Effective date: 20030617 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |